- Home
- VRAX vs RDHL Comparison
VRAX vs RDHL Comparison
Compare VRAX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | RDHL |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United Kingdom | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.6K | 5.4M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | VRAX | RDHL |
|---|---|---|
| Price | $3.06 | $0.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | ★ 728.4K | 145.8K |
| Earning Date | 06-12-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $217,274.83 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.10 | $0.71 |
| 52 Week High | $4.75 | $3.31 |
Technical Indicators
Market Signals| Indicator | VRAX | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 83.18 | 41.48 |
| Support Level | $0.25 | $0.76 |
| Resistance Level | N/A | $0.89 |
| Average True Range (ATR) | 0.30 | 0.07 |
| MACD | 0.32 | -0.00 |
| Stochastic Oscillator | 63.27 | 19.77 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.